Notorious “pharma bro” Martin Shkreli has announced the launch of a Web3 technology-supported drug discovery platform.
The platform, Druglike, is designed to “democratize the costs, access, and rewards” of computational drug discovery, according to a press statement. The company’s website includes a demo of the project along with a white paper, road map and press release.
Druglike arrives just over two months after Shkreli was released from prison.
“We started Druglike because, in our experience, traditional drug discovery software is too difficult and expensive to use,” he said in the statement. “Druglike will remove barriers to early-stage drug discovery, increase innovation and allow a broader group of contributors to share the rewards.”
Shkreli was convicted in July 2017 on two counts of securities fraud and one count of conspiracy to commit securities fraud. While he was sentenced to seven years in prison in 2018, he was released in May.
In January 2022, the Federal Trade Commission banned Shkreli for life from the pharmaceutical industry. The Druglike press release stresses that the company is “a blockchain/Web3 software company and not a pharmaceutical company,” adding that it does not engage in pharmaceutical research or drug development.
Late last month, Shkreli launched Martin’s Newsletter on Substack. The newsletter focuses on investing, science and technology.
